The objective of this contract is to produce, scale-up, characterize and formulate reagent grade (GLP) and /or clinical grade (cGMP) HIV-1vector-based vaccine products for animal and/or human trials. For clinical grade materials the manufacturer must perform all required vaccine lot characterization tests. The contractor must also work together with other contractors performing safety and immunogenicity testing of the vaccine product or producing FDA-required documentation in support of an IND.
| Chege, Gerald K; Burgers, Wendy A; Müller, Tracey L et al. (2017) DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. Vaccine 35:929-937 |
| Burgers, Wendy A; Chege, Gerald K; Muller, Tracey L et al. (2009) Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 90:468-80 |
| Burgers, Wendy A; Shephard, Enid; Monroe, James E et al. (2008) Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 24:195-206 |
| Shephard, Enid; Burgers, Wendy A; Van Harmelen, Joanne H et al. (2008) A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24:207-17 |
